Showing 354 results
November 2021
-
Featured NewsUpdated packaging now available for SANDIMMUNE® 100 mg blister packages
-
Media ReleaseNovartis presents positive Phase III results for Cosentyx® in children with active enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) at ACR 2021Treatment with Cosentyx (secukinumab) resulted in a 72% reduced flare risk versus placebo, with improvement in disease activity over two years across both enthesitis-related arthritis (ERA) and…
-
Media ReleaseNovartis iptacopan meets primary endpoints in Phase II study in rare kidney disease C3 glomerulopathy (C3G)Statistically significant and clinically important reductions in proteinuria were achieved for the primary endpoint for patients with C3G(1) Additionally, statistically significant reduction in C3…
-
Media ReleaseFDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemiaScemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous tyrosine…
October 2021
-
Media ReleaseKesimpta® (ofatumumab) data at ECTRIMS highlights preservation of IgG levels and safety experience over extended exposure (~3.5 years) in people living with relapsing multiple sclerosisALITHIOS Phase IIIb open-label extension study data based on ~3.5 years of exposure demonstrated that mean immunoglobulin G (IgG) levels in patients treated with Kesimpta remained stable, and there…
-
Media ReleaseNovartis announces FDA and EMA filing acceptances of BEOVU® for patients with diabetic macular edemaRegulatory decisions for BEOVU® (brolucizumab-dbll) in diabetic macular edema (DME) are expected in mid-2022 in the US and Europe DME is the leading cause of blindness in adults in developed…
September 2021
-
Media ReleaseNovartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancerWith the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced…
-
Media ReleaseNovartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)PROS is a spectrum of rare disorders caused by PIK3CA mutations and is characterized by atypical, visible overgrowths and anomalies in blood vessels, the lymphatic system and other tissues At 24…
August 2021
-
Media ReleaseNovartis launches "Meet The PROS" to raise awareness and support education for PIK3CA-Related Overgrowth Spectrum (PROS)PROS is a spectrum of at least 13 rare conditions driven by mutations in the PIK3CA gene, typically associated with tissue overgrowth, vascular malformations, and neurological disorders New…
-
Media ReleaseNovartis announces positive results from Phase III trials of BEOVU® in diabetic macular edema, including dosing intervals up to 16 weeksResults from year two of the pivotal Phase III KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one1,2 In key fluid-related…
July 2021
-
Featured NewsBeacon of Hope: Addressing health disparities through holistic community-based collective action
-
Media ReleaseNovartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equityNovartis and the Novartis US Foundation to join forces with Thurgood Marshall College Fund, Morehouse School of Medicine, 26 other Historically Black Colleges, Universities and Medical Schools and…